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Enterococcus species, principally Enterococcus faecium are used as probiotics since a 
long time with preference in animal applications but safety considerations were updated 
and also new uses as probiotics can be envisaged. Fifteen Enterococcus strains 
isolated from different foods were identified and analyzed for virulence factors and 
antibiotic resistance. Three Enterococcus durans strains were selected to study their 
immunomodulatory properties on PBMC and Caco2 cells. Two strains presented a pro-
file toward a mild inflammatory Th1 response considering TNF-α/IL-10 and IL-1β/IL-10 
cytokines ratios. The third strain EP1, presented an anti-inflammatory potential and was 
selected for in vivo studies. In mice, the strain was well tolerated and did not cause any 
adverse effects. EP1 administration increased the amount of IgA+ cells in mesenteric 
lymph node (MLN) after 7  days of administration. In fecal samples, the IgA content 
increased gradually and significantly from day 7 to day 21 in treated group. Additionally, 
IL-17, IL-6, IL-1β, IFN-γ, and CXCL1 gene expression significantly decreased on day 
21 in Peyer’s patches and IL-17 decreased in MLN. Mice treated with the probiotic 
showed significant lower mRNA levels of pro-inflammatory cytokines and mucins in the 
ileum at day 7 while their expression was normalized at day 21. Colonic expression 
of il-1β, il6, and mucins remain diminished at day 21. Ileum and colon explants from 
treated mice stimulated in  vitro with LPS showed a significant reduction in IL-6 and 
an increase in IL-10 secretion suggesting an in vivo protective effect of the probiotic 
treatment against a proinflammatory stimulus. Interestingly, analysis of feces microbiota 
demonstrated that EP1 administration increase the amount of Faecalibacterium praus-
nitzii, a butyrate-producing bacteria, which is known for its anti-inflammatory effects. 
In conclusion, we demonstrated that EP1 strain is a strong sIgA inducer and possess 
Abbreviations: CXCL-1, chemokine (C-X-C motif) ligand 1; GM-CSF, granulocyte macrophage colony-stimulating factor; 
IFN, interferon; IL, interleukin; MLN, mesenteric lymph nodes; PBMC, peripheral blood mononuclear cell; PP, Peyer’s patches; 
TNF, tumor necrosis factor.
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inTrODUcTiOn
Enterococci are an ancient genus of lactic acid bacteria (LAB) 
that are highly adapted to living in complex environments and 
surviving adverse conditions. They are ubiquitous, inhabiting the 
gastrointestinal tracts of a wide variety of animals, from insects 
to man. This widespread pattern of colonization suggests that 
enterococci have been members of the gut microbiome of ancient 
common ancestors (1). Enterococcal strains can be found in a 
variety of fermented foods contributing to the ripening and aroma 
development of certain cheeses or fermented sausages, as well as 
probiotics to improve human or animal health (2, 3). However, 
the genus Enterococcus is a controversial group of LAB consider-
ing that some strains may be associated with human infections 
(4–6). Virulence and pathogenicity factors such as adhesins, 
invasins, pili, and hemolysin have been described principally 
on Enterococcus faecalis and Enterococcus faecium, but other 
enterococcal species occasionally can cause human infections (7). 
Trivedi et al. (8) showed the presence of virulence genes in other 
enterococcal species isolates from foods. Antibiotic-resistant 
enterococci are widespread in food including dairy and meat 
products and can be a potential reservoir of antibiotic resistance 
gene exchanges between enterococci and other species of bacteria 
(2, 9). Therefore, susceptibility to clinically relevant antibiotics of 
Enterococcus strains isolated from food stuffs is very important 
for consumer health.
Enterococcus faecium is one common species used as probi-
otic in animal feed (10) and concerning its safety, the European 
Food Safety Authority (EFSA) edited a new guidance document 
(11) to differentiate between safe and potentially harmful clini-
cal strains, based in their susceptibility to ampicillin and the 
absence of three genetic markers associated with virulence (esp, 
hylEfm, IS16). In animals, enterococcal probiotics are mainly 
used to treat or prevent diarrhea, for immune stimulation or to 
improve growth. For example, E. faecium reduced the portion 
of piglets suffering diarrhea and improved their performances 
(12) or reduced the intestinal colonization by enteropathogenic 
bacteria (13). E. faecium SF68® (NCIMB 10415) approved 
for use as feed additive for different animal productions (14) 
reduced the pathogenic bacterial load in animals declining the 
virulence gene expression of the resident Escherichia coli and 
conferred an anti-inflammatory response (15). Further, SF68 
strain has been reported to possess immune stimulatory effect 
on dogs (16).
Most of human probiotics consist of Lactobacillus spp. and 
Bifidobacterium spp., whereas less information exists about the 
effectiveness of enterococcal strains as probiotics. In humans, 
Enterococcus strains have been used for treatment of diseases 
such as diarrhea or antibiotic associated diarrhea, inflam-
matory pathologies that affects colon such as irritable bowel 
syndrome (IBS), or immune regulation (17). E. faecium SF68 
is specially used for the treatment of diarrhea in children (18) 
and to prevent diarrhea caused by antibiotic treatments, as 
demonstrated for example in a multicenter, placebo-controlled 
double-blinded clinical study (19). Moreover, enterococcal 
strains have been used for health improvement such as lower-
ing cholesterol levels (20, 21).
Now, probiotics can be considered as a therapeutic option 
for treatment of allergy and even for inducing or maintaining 
clinical remission of IBS. E. faecalis Symbioflor 1, an immu-
nomodulatoty strain, has been used to combat recurrent, 
chronic sinusitis or bronchitis and to help to asthma treatment 
in school children (22, 23). E. faecium Paraghurt® has dem-
onstrate its efficacy in lowering the symptoms associated with 
IBS in a clinical study (24) as well as E. faecium PR88 (25) and 
the multi-strains probiotic ProSymbioflor® (E. faecalis and E. 
coli) (26). The probiotic Medilac DS® (E. faecium and Bacillus 
subtilis) has shown to decrease the severity and frequency of 
abdominal pain (27).
Immunomodulatory properties are very important in the 
mode of action of probiotics. Numerous studies analyze the 
immunomodulatory power of different species of Lactobacillus 
and Bifidobacteria in vitro or eventually in vivo. Even though not 
many researchers have studied the immunomodulatory proper-
ties of Enterococcus strains, nowadays the interest in this species 
is increasing. Tarasova et  al. (28) described that E. faecium L5 
was able to restore the microbiota and increase the expression of 
IL-10 and decrease the IL-8 expression in a rat model of dysbiosis. 
Further, studies with E. faecalis CECT 7121 or E. faecium JWS 
833 demonstrated their ability to enhance cytokine production 
on dendritic cells (29, 30).
Avram-Hananel et  al. (31) demonstrated in  vitro and also 
in vivo using a murine model of colitis that Enterococcus durans 
M4-5, a high-butyrate-producing strain induces significant 
anti-inflammatory effects, mediated by regulation of pro- and 
anti-inflammatory immune factors inhibiting the development 
of dextran sodium sulfate (DSS) induced colitis. Similarly, the 
use of E. durans TN-3 alleviates DSS colitis through the induc-
tion of Treg cells and the restoration of the diversity of the gut 
microbiota (32).
In order to select new potentially interesting probiotics, we 
identified several strains of Enterococcus spp. isolated from dif-
ferent sources in order to assess relevant functional and safety 
aspects including presence of virulence genes and susceptibility 
to antibiotics. From 15 isolates, we choose 3 E. durans strains 
to test their anti-inflammatory potential ex vivo. Finally, one E. 
mucosal anti-inflammatory properties. This strain also modulates gut microbiota increas-
ing Faecalibacterium prausnitzii, a functionally important bacterium. Thus, E. durans 
EP1 is not only a good candidate to increases F. prausnitzii in some cases of dysbiosis 
but can also be interesting in gut inflammatory disorders therapy.
Keywords: Enterococcus durans, probiotic, iga, Faecalibacterium prausnitzii, anti-inflammatory
Table 1 | Enterococcus strains used in the study, origin, and presence of virulence genes.
strain Origin species acm gele cyla Vana Vanb Vanc2 agg ccf espfm is16 hylefm
4812 CHU Bordeauxa E. faecium − + + + − − − − + nd nd
5088 CHU Bordeauxa E. faecium − + − − − − − − + nd nd
3091 CHU Bordeauxa E. faecium − − − − − + − − − nd nd
3092 CHU Bordeauxa E. faecium + − − − − − − − − nd nd
6569 ATCC E. faecium + − − − − − − − − − −
29212 ATCC E. faecalis − + + − − − − + − − −
51299 ATCC E. faecalis − + − − + − + + − − −
25390 DSMZ E. faecium nd nd nd nd nd nd nd nd nd + +
5348 CIP E. hirae − − − − − − − − − nd nd
EP1 Cow milkb E. durans − − − − − − − − − − −
EP2 Cow milkb E. durans − − − − − − − − − − −
EP3 Cow milkb E. durans − − − − − − − − − − −
109 Chicken intestine E. faecium + − − − − − − − − − −
433 Chicken intestine E. faecium + − − − − − − − − − −
440 Chicken intestine E. faecium + − − − − − − − − − −
537 Chicken intestine E. faecium + − − − − − − − − − −
545 Chicken intestine E. faecium + − − − − − − − − − −
555 Chicken intestine E. hirae − − − − − − − − − − −
68 Probioticc E. faecium + − − − − − − − − − −
638 Chicken intestine E. faecium + − − − − − − − − − −
1439 Goat cheese E. faecium + − − − − − − − − − −
1440 Sheep milkd E. faecium + − − − − − − − − − −
1442 Sheep milkd E. faecium + − − − − − − − − − −
1443 Sheep milkd E. durans − − − − − − − − − − −
aCentre Hospitalo-Universitaire de Bordeaux, France.
bCow milk origin Argentina.
cSpring Valley (USA).
dSheep milk origin Spain.
CIP, Collection of Institut Pasteur.
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durans strain was selected to performed studies in healthy mice 
in order to analyze mucosal immunomodulatory capacities and 
its ability to modulate intestinal microbiota.
MaTerials anD MeThODs
bacterial strains and growth conditions
Enterococcus strains isolated from different sources were used in 
this work as well as several collection strains, all of them all listed 
in Table 1. These bacteria were grown using M17 broth (DIFCO, 
Detroit, MI, USA) in agitation at 37°C for 24 h.
Other strains used in this work were S. aureus ATCC 6538, 
Shigella flexneri ATCC 9199, Pseudomonas aeruginosa ATCC 
15442, a clinical isolate Salmonella enterica serovar Enteritidis 
CIDCA 101 (Hospital de Pediatría Prof. Juan P. Garrahan, Buenos 
Aires, Argentina), enterohaemorragic Escherichia coli EDL 933, 
Bacillus cereus ATCC 10876, and Listeria monocytogenes ATCC 
7644. All strains were grown in brain heart infusion broth 
(BIOKAR) in aerobic conditions at 37°C for 16 h.
Molecular identification
Genomic DNA from Enterococcus strains was extracted using the 
Genomic DNA Purification Kit (Fermentas, France) according to 
manufacturer’s specifications.
Species identification were confirmed by 16S rDNA gene 
sequencing and species-specific primers based on the superoxide 
dismutase (sodA) gene (33, 34).
In Vitro safety evaluation
Detection of Virulence Genes
All isolates were tested for the presence of the three genetic ele-
ments considered relevant for EFSA (11): enterococcal surface 
protein (esp), IS16, and hylEfm. Other virulence genes included in 
this study were sex pheromones (ccf), gelatinase (gelE), cytolysin 
(cylA), aggregation substance (agg) (35), cell-wall anchored col-
lagen adhesin (acm) (36), and van A, van B, van C2 (37). Positive 
controls were used in all PCR reactions (Table 1).
Antibiotic Susceptibility and Hemolytic Activity
Susceptibility to antibiotics was evaluated as described previ-
ously (34). Briefly, the disk diffusion method (38) was used for 
ciprofloxacin, gentamicin, sulfamethoxazole  +  trimethoprim, 
linezolid, and vancomycin. In the case of ampicillin, the minimum 
inhibitory concentration was determined by broth microdilution 
according to ISO 20776-1 (39).
Hemolysis was tested by growth of the strains on Columbia 
agar (bioMérieux, France) supplemented with 5% human blood 
(group O) and incubated for 48 h at 37°C under aerobic condi-
tions (34).
growth inhibition of bacterial Pathogens
An agar spot test was performed to assess antimicrobial proper-
ties as described previously (34). Inhibition was considered 
negative if the width of the clear zone around the colonies 
was less than 2 mm, a low inhibition capacity was considered 
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if the width of the clear zone ranged between 2 and 5  mm, 
and a high inhibition capacity was considered if the width 
was 6  mm or larger. Three independent experiments were 
performed.
resistance to gastrointestinal Tract 
conditions and adhesion to Mucin and 
caco-2 cells
Resistance to simulated gastric and intestinal compartments was 
assessed as previously described (34). Briefly, bacterial suspen-
sions were incubated sequentially in solutions simulating the 
gastric and intestinal compartments. Initially, bacteria suspen-
sions were incubated at 37°C with stirring at 200 rpm for 90 min 
in simulated gastric fluid (in w/v: 0.73% NaCl, 0.05% KCl, 0.4% 
NaHCO3, and 0.3% pepsin) at pH 2.5. Afterward bacteria were 
resuspended in simulated intestinal fluid (comprising 0.1%, 
w/v, pancreatin and 0.15%, w/v, bovine bile salts) at pH 8.0 and 
incubated at 37°C with stirring at 200 rpm for 3 h. Cell viability 
was assessed by plate counting. Independent experiments were 
performed at least three times.
Bacterial binding assays were performed using bacteria 
before and after performing the gastrointestinal tract simula-
tion experiment. Bacterial binding assays to commercial type 
III porcine gastric mucin (Sigma-Aldrich) were performed as 
described previously (40) and adhesion to Caco-2 cells were 
performed following the protocol described by Minnaard et al. 
(41). Independent experiments were performed at least three 
times.
PbMc and caco-2 stimulation 
experiments
PBMC and Caco-2 Preparation and Stimulation
Peripheral blood samples were obtained from healthy blood 
donors (Regional Blood Transfusion Center, EFS Aquitaine, 
Bordeaux, France), and all subjects gave written informed con-
sent in accordance with the Declaration of Helsinki. PBMC were 
isolated on Ficoll hypaque gradients as described previously (42). 
Caco-2 cells were cultured as described previously (40).
For cells stimulation experiments, bacteria in stationary 
phase of growth were harvested by centrifugation and washed 
three times with PBS. Stimulation experiments were performed 
by coculturing 2 × 107 of bacteria per well (MOI = 10). Culture 
supernatants were collected after 24 h of culture, and triplicates 
were kept at −80°C until cytokine analysis. Cells were detached 
by mechanical scraping in order to check their viability using the 
protocol (MTT) described by Minnaard et al. (41) or preserved 
in RNAlater (QIAGEN, Hilden, Germany) for gene expression 
studies.
Quantification of Cytokine Levels in Cell Culture 
Supernatants
The cytokine profiles were analyzed after E. durans strains 
stimulation of PBMC using the human Th1/Th2 11plex 
FlowCytomix Kit (eBioscience). It was designed to measure 
human IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, 
IL-12 p70, TNF-α, and TNF-β. Analysis was performed in a 
flow cytometer BD Accuri C6 (BD Biosciences). TGF-β was 
measured using the eBioscience human/mouse TGF beta 1 
Ready-SET-Go!® ELISA Kit.
Quantification of Gene Expression in Caco-2 by 
qRT-PCR
Total RNA was isolated using the RNeasy Mini Kit (QIAGEN, 
Hilden, Germany) with an additional DNase treatment (Turbo 
DNA-free, Ambion, Inc.) according to the manufacturer’s instruc-
tions. One microgram of total RNA was reverse transcribed 
using the Maxima® Reverse Transcriptase (Fermentas, France) 
with anchored-oligo (dT) 18 primer. Quantitative real-time 
PCR analyses were performed using a CHROMO 4™ System 
(Bio-Rad). The reaction mixture comprised Maxima SYBR 
Green/ROX qPCR Master Mix (Fermentas, France). Target gene 
copy numbers were normalized against the housekeeping genes 
hypoxanthine phosphoribosyltransferase and β2 microglobulin 
(B2m). Genes evaluated: il1b, il6, and il8.
In Vivo experiments
Mice
Male Swiss albine mice, 5-week-old (Janvier, Le Genest-Saint-Isle, 
France) were quarantined 2 weeks after arrival and were housed 
under standard laboratory conditions with free access to food and 
water. The temperature was kept at 22°C, and a 12-h light/dark 
schedule was maintained. Mice were divided into two groups 
(n = 12/group) and received by gavage 108 CFU of E. durans EP1 
(EP group) or PBS (control group) daily for 7 and 21  days; at 
each time point six mice were sacrificed. This study was carried 
out in accordance with the recommendations of the European 
Economic Community (directive 2010/63/UE). The protocol was 
approved by the Animal Research Committee of the Agriculture 
Ministry and the Ethical Committee C2EA50.
Safety Evaluation
Mice were weighted every 2 days, behavior and signs of pain were 
analyzed daily.
At the end of the experimental protocol, ileum and colon sec-
tions were preserved for histological studies and liver and spleen 
were removed and blood samples were collected aseptically. 
Liver and spleen were homogenized in 0.1% sterile PBS (0.1 g of 
organ per mL), and ileum content was washed with sterile PBS, 
and serially diluted. The dilutions were plated on violet red bile 
glucose (VRBG) Agar (Biokard Diagnostic, Beauvais, France) 
for enterobacteria, De Man, Rogosa and Sharpe (MRS) agar for 
LAB, and Yeast extract glucose chloramphenicol (YGC) agar for 
yeasts. Plates were incubated under anaerobic conditions for 24 h 
at 37°C for VRBG and YGC, and for 48 h at 37°C for MRS, before 
examination (40).
Tissue and Stool Sampling
Stools were collected at days 7, 14, and 21 and stored at −80°C 
until analysis. At the end of the experimental protocol, days 
7 or 21, ileum and colon samples were collected and were 
preserved at −20°C in RNAlater. On day 21, Peyer’s patches 
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(PP) and mesenteric lymph nodes (MLN) were also removed 
and preserved at −20°C in RNAlater for expression analysis, 
and ileum and colon sections were collected in RPMI medium.
Reactivity of Ileum and Colon Explants to LPS
Ileum and colon explants were cultured in RPMI 1640 supple-
mented with 10% bovine fetal serum and antibiotics, in presence 
or absence of 10 µg/mL of LPS from E. coli as proinflammatory 
stimulus (all from Sigma Chemical Co., St. Louis, MO, USA) 
for 24  h at 37°C in an atmosphere of 95% air and 5% CO2 
as described previously (40, 42). Supernatants were collected, 
centrifuged, and frozen until cytokine (IL-6, IL-4, IL-10, IL-17A, 
IFN-γ, and GM-CSF) measurements (Ready-SET-Go!® ELISA 
Kit, eBioscience, France). All assays were performed according 
to the manufacturer’s instructions.
Quantification of Gene Expression in Mouse Ileum, 
Colon, MLN, and PP Samples by qRT-PCR
The same procedures described in the section “Quantification of 
Gene Expression in Caco-2 by qRT-PCR” were used. Cytokine 
and chemokine genes evaluated were il1b, il6, il10, il12p70, 
il17a, il23, ifng, tnfa, tgfb, cxcl1, baff, april, and gmcsf; the 
transcription factors studied were foxp3 and rorgt; epithelial 
barrier and IgA-related genes were zo-1, occludin, and pIgR; 
mucin genes muc1, muc2, muc3, muc4, muc6, and muc13. 
Primer sequences and PCR conditions are available upon 
request.
Determination of Total IgA in Stools
On days 7, 14, and 21 of the experimental protocol the level 
of total IgA in stools was measured by ELISA according to the 
technique described by BD Pharmigen. Briefly, Maxisorp Nunc 
plates were coated overnight with purified rat anti-mouse IgA 
(BD 556969), washed with PBS containing 0.05% v/v Tween 
20 (PBS-T), and blocked with FBS 10% v/v in PBS. Plates were 
incubated for 2 h at room temperature with purified mouse IgA 
kappa (BD 553476) or fecal samples. Plates were revealed using 
biotin rat anti-mouse IgA (BD 556978), streptavidin horseradish 
peroxidase (BD 554066), and trimethylbenzidine (TMB substrate 
reagent set BD OptEIA 555214). All determinations were per-
formed in triplicate.
Fecal Microbiota Evaluation
Qualitative Analysis by PCR-DGGE
The experiments were performed as described previously 
(42). Briefly, HDA1 and HDA2-GC primers were used to 
assess microbial diversity in each sample. PCR products were 
separated in 8% polyacrylamide gels with a range of 30–50% 
denaturing gradient (100% denaturant consisted of 7  M urea 
and 40% deionized formamide) cast with Bio-Rad’s Model 475 
gradient delivery system (BioRad, Hercules, CA, USA). The 
electrophoresis was performed in TAE 0.5× buffer for 5 h at a 
constant electric current of 125 mA and a temperature of 60°C 
with the DCode Mutation Detection System (Bio-Rad, Hercules, 
CA, USA). Clustering analysis was performed using the UPGMA 
(unweighted pair group method with arithmetic mean clustering 
algorithm) to calculate the dendrograms.
Microbiota Population Analysis in Feces by q-PCR
Microbiota population analysis in feces was performed on the day 
21 of the experience as described previously (42). Briefly, DNA was 
extracted using the NucleoSpin Soil Genomic DNA isolation kit 
(Macherey-Nagel), and the quantification of bacterial populations 
was carried out using primers synthesized by Biomers (France). 
The populations evaluated were: Firmicutes, Lactobacillus 
spp., Lactobacillus murinus, Lactobacillus acidophilus group, 
Clostridium leptum group, Clostridium perfringens, Clostridium 
coccoides group, Faecalibacterium prausnitzii, segmented filamen-
tous bacteria, Enterobacteriaceae, E. coli, Bacteroidetes, Bacteroides 
fragilis group, Prevotella group, Akkermansia muciniphila, 
and Bifidobacterium (42). PCR reactions were performed on a 
CHROMO 4™ System (Bio-Rad) using Maxima SYBR Green/
ROX qPCR Master Mix (Fermentas, France).
statistical analysis
Statistical comparisons for significant differences were performed 
according to the Student’s t-test. p Value <0.05 was considered as 
statistically significant.
resUlTs
strain identification and safety 
assessment
In this study, 15 bacteria were identified to species level by 16S 
rDNA gene sequencing (43) and species-specific primers based 
on superoxide dismutase (sodA) gene (33). Ten strains out of 15 
were identified as E. faecium, 4 as E. durans, and 1 as Enterococcus 
hirae.
Once identified, safety aspects were evaluated. None of the 
four E. durans strains were positive for any virulence or vanco-
mycin resistance genes and the same results were obtained for 
E. hirae (Table 1). In contrast, all 10 food and animal E. faecium 
isolates were positive for acm (Table 1). It is important to notice 
that neither E. faecium nor E. durans strains was α-hemolytic. 
Regarding antibiotic resistance, 90% of E. faecium strains and E. 
hirae were resistant to two or more antibiotics, while only 25% of 
E. durans strains showed this profile (data not shown).
Considering the described results, three E. durans strains 
were selected to perform in vitro studies on PBMC and Caco-2 
cell line.
E. durans strains stimulates PbMc and 
Modulates Proinflammatory Molecules on 
caco-2 cells
The three strains of E. durans (EP1, EP2, and EP3) chosen after 
in  vitro safety evaluation were cocultured with human PBMC 
and Caco-2 cells. Secreted cytokines and gene expression was 
assessed.
On PBMC, quantification of secreted cytokines in superna-
tant showed a similar pattern for the three strains under study 
(Table 2). All of them increased IL-1β, IL-6, IL-12p70, IFN-γ, and 
TNF-α as well as IL-10. However, EP1 induced the lowest TNF-α/
IL-10, IL-1β/IL-10, and IL-12/IL-10 ratios (Table 2), suggesting 
that EP1 is a better anti-inflammatory candidate (44).
FigUre 1 | Probiotic properties of eP1. (a) Resistance to simulated 
gastrointestinal conditions. (b) Percentage of adhesion to Caco-2 cell line 
and gastric mucin of EP1 cells and EP1 cells post-gastrointestinal tract 
simulation. Results are expressed as mean ± SD and are representative of at 
least three independent experiments (*p < 0.05).
Table 2 | cytokine production by PbMc and selected cytokine ratio after 48-h exposure to E. durans strains.
eP1 eP2 eP3 control PbMc
cytokine (pg/ml)
IL-1β 1,226 ± 13b 2,025 ± 25b 1,642 ± 180b 25 ± 12a
IL-6 3,762 ± 256b 3,362 ± 210b 3,785 ± 169b 66 ± 19a
IL-8 3,368 ± 425a 4,585 ± 769a 3,685 ± 225a 4,153 ± 211a
TNF-α 7,315 ± 3,861b 24,508 ± 3,354c 20,261 ± 5,499c 228 ± 43a
IFN-γ 118 ± 16b 66 ± 9b 109 ± 4b 8 ± 2a
IL12p70 871 ± 30b 1,011 ± 57b 1,183 ± 27b 403 ± 162a
IL-10 1,171 ± 41b 1,345 ± 36b 1,485 ± 351b 6 ± 2a
cytokine ratio
IL-1β/IL-10 1.05 1.50 1.11 4.17
IL-12/IL-10 0.74 0.75 0.80 67.17
TNF-α/IL-10 6.25 18.22 13.64 38.00
Means with the same letter for each parameter are not significantly different.
6
Carasi et al. Enterococcus durans as Immunobiotic
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 88
Stimulation assays performed with confluent Caco-2 cells also 
revealed differences between strains. EP2 increased expression of 
IL-6 (p < 0.05) but did not affect IL-1β and IL-8 expression. On 
the other hand, EP1 decreased expression of IL-1β, IL-6, and IL-8 
(p < 0.05), while EP3 did not affect expression of any tested genes 
(data not shown).
Considering all the obtained results, the strain E. durans 
EP1 was selected to evaluate probiotic properties and its in vivo 
immunomodulatory effect in mice.
eP1 resists gastrointestinal conditions 
without Modifying its adhesion capacity 
and also inhibits growth of gram-Positive 
and -negative Pathogens
The ability of E. durans EP1 to survive to the simulated gastro-
intestinal conditions was assessed. Viability was not affected by 
gastric step. On the contrary, the critical step was the intestinal 
passage which lowered viability significantly around one loga-
rithmic unit.
On the other hand, E. durans EP1 presented a moderate adhe-
sion capacity (around 6–8%) to both porcine gastric mucin and 
Caco-2 cells, which was not affected by the passage through the 
gastrointestinal tract simulation (Figure 1).
Moreover, E. durans EP1 is able to inhibit the growth of patho-
gens in vitro. We observed that EP1 exerts a powerful inhibitory 
effect on S. aureus and L. monocytogenes and a moderated effect 
on E. coli, S. flexneri, S. enterica, and P. aeruginosa (Table 3). On 
the contrary, B. cereus and E. faecalis were slightly or not inhibited.
In Vivo studies
Enterococcus durans EP1 Shows No Deleterious 
Effect on Swiss Mice
There were no differences in food and water intake between 
mice that received 100  µL of a 109  CFU  mL−1 suspension of 
E. durans EP1 (EP1 group) and mice receiving 100 µL of PBS 
(control group) daily for 21 days (data not shown). Moreover, 
no differences in body weight were observed between groups 
(Figure 2A). EP1 group did not show any signs of pain, lethargy, 
dehydration, or diarrhea during treatment. In accordance with 
these observations, no signs of inflammation or damage were 
observed in any organ during necropsy, and no significant differ-
ences in colon’s length (45) between EP1 and control mice were 
observed (12.4 ± 0.5 vs 12.6 ± 0.8 cm; Figure 2B). Finally, the 
histological evaluation of ileum and colon sections of EP1 group 
did not show any signs of inflammation, such as edema, erosion/
ulceration, crypt loss, or infiltration of mono- and polymorpho-
nuclear cells (data not shown). On the other hand, no bacterial 
FigUre 3 | impact of eP1 administration on siga. (a) IgA quantification 
from fecal samples taken on day 7, 14, or 21 from control mice and 
EP1-treated mice (EP1). (b) Percentage of IgA+ cells in mesenteric lymph 
node and Peyer’s Patches after 7 days of EP1 administration. Results are 
expressed as mean ± SD. No significant differences (n.s.); *p < 0.01; 
**p < 0.001.
FigUre 2 | Enterococcus durans eP1 administration for 21 days had 
no deleterious effect on swiss mice. (a) Body weight gain of treated 
(EP1) and control mice. (b) Colon length at the end of the experimental 
protocol, results expressed as mean ± SD.
Table 3 | growth inhibition of bacterial pathogens by eP1.
gram-positive pathogens R 
(mm)
gram-negative pathogens R 
(mm)
Shigella flexneri ATCC 9199 7 Listeria monocytogenes ATCC 
7644
15
Pseudomonas. aeruginosa 
ATCC 15442
9 S. aureus ATCC 6538 12
Salmonella enterica CIDCA 
101
5 Enterococcus faecalis ATCC 
29212
3
EHEC EDL933 5 Bacillus cereus ATCC 10876 <1
EHEC, enterohaemorragic Escherichia coli; R, width of clear zone around colony.
No inhibition (width of the clear zone around colony <2 mm); low inhibition capacity 
(width of the clear zone around colony between 2 and 5 mm); high inhibition capacity 
(width of clear zone around colony >6 mm).
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growth was observed in any of the used cultured media, thus no 
translocation of microorganisms to blood, spleen, or liver was 
observed.
Enterococcus durans EP1 Administration Increases 
sIgA in Feces
Total sIgA concentration was increased in mice stools after 
treatment with EP1. SIgA increases progressively throughout 
the treatment (Figure  3A). The average increment of secreted 
sIgA after 1  week of probiotic administration was of 0.7 times 
meanwhile increments of 3.2 and 5.75 relative to control group 
were observed after 2 and 3 weeks, respectively (Figure 3A).
Even though the increment of secreted sIgA was not signifi-
cantly increased after 7 days of EP1 administration, the number 
of IgA+ cells was significantly higher in MLN of treated mice than 
in control mice (Figure 3B). In contrast, this was not observed in 
Peyer’s Patches (Figure 3B).
Enterococcus durans EP1 Downregulates the 
Expression of Proinflammatory Molecules and 
Mucins in Ileum and Modifies Its Reactivity to LPS
The effect of E. durans EP1 administration on ileum gene expres-
sion was assessed after 7 and 21 days of treatment. The analysis 
of cytokines’ and chemokines’ expression showed a decrease 
in mRNA amounts of the proinflammatory molecules il6, il1b, 
il12p70, and tnf-a after 7 days, but no differences in expression 
after 21  days of administration (Figure  4A) were observed. 
Interestingly, mucin genes were also downregulated at the first 
week of probiotic treatment but after a longer administration 
period the expression of these molecules returned to the levels 
observed in control mice (Figure 4B).
Thereupon, we decided to assess ileum reactivity by cultur-
ing tissue sections in presence or absence of the proinflamma-
tory stimuli LPS. We observed that ileum sections from 21 days 
EP1 treated mice without any stimulation secreted lower 
quantities of IL-6 (Figure  4C) and higher amounts of IL-10 
(165 ±  57 vs 25 ±  12  pg/mL) than control mice. Moreover, 
LPS stimulation induced lower amounts of GM-CSF and IL-6 
in EP1 group (Figure 4C). Levels of IL-4, TNF-α, IL-17A, and 
IFN-γ were not modified after stimulation in either group (data 
not shown).
E. durans Reduces Proinflammatory Cytokines 
Levels and Mucins Expression in Colon and 
Increases IL-10 Secretion in Response to LPS 
Stimulation
EP1 consumption decreased il6, il1b, and cxcl-1 expression after 
7 days, and this downregulation was persistent for the first two 
genes after 21 days of probiotic treatment (Figure 5A). On the 
other hand, mucin-encoding genes showed a decreased expres-
sion after 1 and 3  weeks of EP1 administration (Figure  5B). 
Afterward, reactivity to LPS was assessed. As shown in Figure 5C, 
not stimulated colon explants from 21  days EP1-treated mice 
secreted lower amounts of IL6 and higher quantities of IL10 than 
control mice. In accordance, the proinflammatory stimuli LPS 
produced a lower increment of GM-CSF and IL-6 in EP1 group 
and a higher secretion of IL-10 (Figure 5C). As it was observed in 
ileum explants, levels of IL-4, TNF-α, IL-17A, and IFN-γ showed 
no changes after stimulation (data not shown).
E. durans Decreases the Expression of 
Proinflammatory Cytokines in MLN and PP
Since immune modulation was observed in ileum and colon 
from mice treated with EP1, we decided to evaluate the impact 
FigUre 4 | effect of eP1 administration on ileum. (a) Expression of cytokines and chemokines. (b) Expression of genes related with intestinal epithelial barrier 
function. (c) Cytokines in supernatants of 21 days treated ileum explants cultured for 48 h in the absence or presence of LPS. Results are expressed as mean ± SD 
(*p < 0.01).
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of probiotic administration in the induction sites MLN and PP. 
We observed that treatment with EP1 during 21 days decreased 
the expression of the proinflammatory molecules il1b, il6, ifng, 
and cxcl-1 only in PP while il-17 was reduced in both MLN and 
PP (Figure 6). This last result is particularly interesting since EP1 
not only decreased the expression of Th1 related genes but also 
Th17-related molecules.
EP1 Administration Increases F. prausnitzii Amount 
in Mice Stools
The impact of EP1 administration in fecal microbiota was 
assessed by qualitative (PCR-DGGE) and quantitative (qPCR) 
methods. The number of PCR-DGGE amplified bands can be 
related with microbial diversity. No significant differences were 
observed between control and EP1 mice (32 ±  3 vs 34 ±  4) 
indicating that the probiotic does not alter bacterial diversity in 
healthy conditions. However, the cluster analysis based on the 
Pearson product-moment correlation coefficient and UPGMA 
linkage allowed differentiation of the experimental groups in two 
clusters which indicates changes in the microbial community 
composition due to probiotic administration (Figure 7A).
The parameters initially evaluated by qPCR were total bacte-
rial load, Firmicutes/Bacteroidetes ratio, and Enterobacteriaceae 
quantities, particularly E. coli, since changes in these parameters 
are associated with non-healthy microbiota (46). In correlation 
with the results exposed previously in this work, no changes in 
the mentioned parameters were observed in mice treated with 
EP1. As expected, the quantitative methods revealed an incre-
ment in Enterococcus population (Figure  7B). Interestingly, an 
increment in the Gram-positive butyrate-producing bacterium 
FigUre 5 | effect of eP1 administration in colon. (a) Expression of cytokines and chemokines. (b) Expression of genes related with intestinal epithelial barrier 
function. (c) Cytokines in supernatants of 21 days treated colon explants cultured for 48 h in the absence or presence of LPS. Results are expressed as mean ± SD 
(*p < 0.01).
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F. prausnitzii belonging to Clostridium cluster IV, was detected in 
stools from EP1-treated mice (Figure 7B). No significant changes 
were observed in any other quantified population, not even in A. 
muciniphila which was perhaps expected to be affected due to 
the decrease in mucin expression in EP1-treated mice compared 
with controls.
DiscUssiOn
Enterococcus strains have been used as long time as effective 
probiotics but this bacterial group can also harbor pathogenic 
strains. In this context, it is indispensable to analyze the pres-
ence of virulence factors and antibiotic resistances. Generally, 
the frequency of pathogenic strains is higher in E. faecalis and 
E. faecium; however, some authors have retrieved occasionally E. 
durans isolates from foods or healthy children stools possessing 
virulence factors (8, 47). The strain that we selected, E. durans 
EP1, is in agreement with the requirements established by the 
EFSA (11). Furthermore, no deleterious effect was observed in 
mice that received EP1 for 21 days.
Adhesion to gastrointestinal mucus and epithelial cells has 
an important role in the probiotic effect and can be related to 
the immunomodulation properties (48). EP1 presents a moder-
ate adhesion to mucin and Caco-2 cells (around 6–8%) such 
as described for some Bifidobacteria and Lactobacillus strains 
(48–50). Interestingly, this property is not affected after gastroin-
testinal tract passage simulation.
In order to screen the immunomodulatory activity of the 
selected E. durans strains, we used PBMC from healthy donors 
and the results obtained were strain dependent. Considering the 
pro-inflammatory/anti-inflammatory cytokines ratio, the lower 
values were obtained for EP1 suggesting that this strain has better 
anti-inflammatory potentiality. In this sense, other authors have 
demonstrated the correlation between this ratio and the in vivo 
anti-inflammatory expected effect (42, 44, 51). In our in  vivo 
study, we also corroborate the predictive power of these ratios.
FigUre 7 | impact of treatment with eP1 for 21 days on fecal microbiota. (a) Total bacteria DGGE profiles and dendrogram of five mice from control group 
(C1–C5) and five from EP group (lanes EP1–EP5). Clustering analysis was performed using the UPGMA linkage. (b) qPCR quantification results for Firmicutes/
Bacteroidetes ratio, and total count for Enterococcus spp and Faecalibacterium prausnitzii (*p < 0.05).
FigUre 6 | gene expression in mucosal induction sites after 21 days of eP1 administration, (a) mesenteric lymph nodes (b) Peyer’s patches. Results 
are expressed as mean ± SD (*p < 0.05).
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Most of the studies performed to evaluate the effects of 
probiotics on the immune system use animal disease models. 
Of equal or higher interest is the study of immune modulation 
in healthy individuals as the knowledge acquired can be used to 
prevent specific pathologies or disease development (52–54). To 
gain insight in how E. durans EP1 modulates the immune system, 
healthy mice were treated orally with the strain for 21  days. 
After 1  week of probiotic treatment, expression of proinflam-
matory cytokines was downregulated in both ileum and colon. 
On the 21st day, expression levels of all the evaluated genes 
in ileum returned to those found in control mice meanwhile 
in colon proinflammatory cytokines were still downregulated. 
The differences in expression observed between tissues could 
be related to the presence of EP1 in each section of the gut 
or with modifications in the quantity and composition of the 
local microbiota as well as differences in the thickness of the 
mucus layer that may affect bacterial interaction with host’s cells 
(52, 55, 56). Similar results were obtained by Smelt et al. (52), 
who evaluated the impact of several Lactobacillus and observed 
distinct changes in lamina propia of small and large intestine 
of healthy mice.
Despite of the differences in mRNA quantities in ileum and 
colon after 21 days of treatment, a lower basal secretion of IL-6 
and a higher of IL-10 were observed in tissue explants from EP1-
treated mice. Moreover, EP1 showed significant anti-inflamma-
tory effect, as evidenced by the suppression of LPS-induced IL-6 
and GM-CSF levels in both tissues explants and upregulation of 
IL-10 amounts in colon. In accordance with these results, several 
proinflammatory cytokine genes were downregulated in PP and 
IL17 in MLN at day 21. The described findings suggest that this 
strain could have a positive effect on intestinal inflammation 
(44, 57). Even though the overall anti-inflammatory phenotype 
of EP1 is similar to that of Lactobacillus kefiri CIDCA 8348 
(same cytokine ratio after PBMC stimulation and similar anti-
inflammatory response of intestinal explants to LPS), there are 
differences in the mucosal response in  vivo. E. durans reduces 
IL-6 expression in colon which appears be concomitant with the 
decrease in the expression of genes involved in mucins produc-
tion. On the contrary, L. kefiri does not affect IL-6 expression 
and upregulates mucins genes [Ref. (42), see below]. These data 
further corroborate that mucosal immunity and homeostatic 
properties of probiotics are strain specific.
An important finding of the present study was that the 
administration of EP1 strain resulted in higher IgA content in 
feces. Fourteen days of probiotic treatment was sufficient to 
increase stools IgA levels five times, and after 21 days, the IgA 
level was increased near six times. Secretory IgA, the predomi-
nant immunoglobulin class in human external secretions, is a 
key element in the maintenance of gut microbiota homeostasis 
and in the protection of the mucosal epithelia against pathogens 
(58) and its induction has been described for other probiotic 
bacteria (59, 60). The production of sIgA decreases with age 
can lead to an increased risk of infection (61). In this context, 
Lefevre et  al. (62) showed that the consumption of a Bacillus 
subtilis probiotic (CU1) significantly increases intestinal and 
salivary sIgA in seniors helping a decreased the frequency of 
respiratory infections.
As a result of probiotic stimulation the IgA cycle can be 
induced and the number of IgA+ cells in mucosal sites distant 
to the intestine can be increased (63). We observed a significant 
augmentation in IgA-producing cells in the MLN of mice treated 
with the E. durans EP1. These results are in accordance with 
the effect observed in L. kefiri CIDCA 8348 that occasioned an 
increment in IgA+ B cells in MLN correlating with an increase 
of IgA in fecal samples (42). It is interesting to note that sIgA 
has a dual function, (i) preventing overgrowth of the gut micro-
biota and (ii) also minimizing its interactions with the mucosal 
immune system, diminishing the host’s reaction to its resident 
microbes (64).
Another important feature on mucosal physiology is the mucus 
layer. Mucins are the main component of the mucus layer and it 
has been described that their production could be modified by 
changes in host microbiota induced by diet changes, infections, 
probiotic, or antibiotic treatments (65–67). EP1 administration 
decreased the expression of mucins in both ileum and colon. The 
observed downregulation could be explained by a direct effect 
of E. durans EP1 on mucosa or as a result of changes induced 
in mice microbiota after probiotic treatment. The increment 
in Faecalibacterium prausnitzii is of interest since it has been 
described that it can modulate the effects of other bacteria on 
goblet cells and thus decrease mucus production and mucin 
glycosylation (68).
Even though it has been proposed that thinning of the mucus 
layer may increase contact between epithelial cells and bacteria 
present in the microbiota, augmenting the inflammatory tone 
of the intestine, this effect was not observed in this study. The 
fact that sIgA is increased in EP1 mice may be related with this 
observation since it has been described that microbiota are linked 
with sIgA to control intestinal homeostasis and that spatial segre-
gation of pathobionts from the intestinal wall occurs as a result of 
intraluminal agglutination in an extracellular matrix consisting 
of sIgA, polymeric immunoglobulin receptor, and epithelial 
cadherin (E-cadherin) proteins (64, 69). Moreover, increased 
expression of mucins is often associated with invasive bacteria 
and inflammatory conditions (70–72). In accordance with our 
results, Levkut et al. (73) observed that E. faecium administration 
to broilers induced a decrease in mucus layer density. Interestingly, 
the probiotic treatment exerted a protective effect when chickens 
were challenged with Salmonella.
It is known that an active dialog exists between the com-
mensal microorganisms and the host mucosal immune system 
(63, 74). Probiotics may help to maintain immune functions and 
mucosal homeostasis either by direct interaction with the host or 
indirectly by re-equilibrating or modulating the gut microbiota 
(75, 76). Enterococcus species are known to be great antimicrobial 
producers (17, 77), a good example was shown by Nami et al. (78) 
using the E. durans strain 6HL isolated from the vagina of heathy 
women. In this work, we observed that E. durans EP1 produces 
antimicrobials substances since it inhibits growth of several 
pathogens in vitro. These secreted substances can be implicated 
in microbiota modulation. Analysis of mice microbiota demon-
strated that EP1 administration increased F. prausnitzii, while 
all other tested populations remained unchanged. Unexpected 
was the preservation of A. muciniphila count since this bacteria 
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is a mucin-degrading member of the intestinal microbiota (79) 
and could have been affected by the decrease in mucin gene 
expression.
Faecalibacterium prausnitzii is one of the most abundant bac-
teria in the human gut ecosystem, and it is an important supplier 
of butyrate to the colonic epithelium (80). We hypothesized that 
F. prausnitzii resists better the antimicrobials molecules produced 
by EP1 than the other members of C. leptum group (cluster IV). 
Interesting, F. prausnitzii, a member of the human microbiota 
“core” is very important for intestinal homeostasis maintenance 
and is known to elicit strong anti-inflammatory responses. In fact, 
F. prausnitzii has been associated with longer remission periods 
in Crohn’s disease patients (80). Moreover, F. prausnitzii increases 
Treg cells counts in which suggests their therapeutic potential for 
the treatment of diseases associated with loss of tolerance (81). 
We presume that the increment of F. prausnitzii in mice treated 
with E. durans EP1 is involved in the anti-inflammatory effects 
observed in mice mucosa.
cOnclUsiOn
Enterococcus durans strain EP1, selected by the evaluation of 
pro-inflammatory/anti-inflammatory cytokines ratio in PBMC, 
has no virulence factors and has no deleterious effect on mice. We 
demonstrated that this strain is a strong sIgA inducer and possess 
anti-inflammatory properties, downregulating the expression 
of pro-inflammatory cytokines in the intestinal mucosa and 
inducing the secretion of IL-10. EP1 modulates gut microbiota 
increasing the anti-inflammatory bacteria F. prausnitzii that could 
be implicated also in the observed anti-inflammatory responses.
Thus, E. durans EP1 is not only a good candidate to increases 
F. prausnitzii in elderly population or other dysbiotic situations 
but also for gut inflammatory disorders therapy. We will continue 
the study of this strain in a mice model of inflammation in our 
laboratory.
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